Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
Nutrients. 2023 Mar 16;15(6):1445. doi: 10.3390/nu15061445.
Non-alcoholic fatty liver disease (NAFLD) is a potentially progressive condition characterized by the presence of fat in more than 5% of hepatocytes, representing the hepatic expression of metabolic syndrome (MetS). A reduction of at least 5-7% in initial body weight improves the metabolic profile underlying NAFLD. The aim of our study was to evaluate the effects of the COVID-19 lockdown on a cohort of non-advanced NAFLD Italian outpatients. We identified 43 patients with 3 available time point visits in our center: first visit (T0) when behavioral indications aimed at controlling MetS were provided, a pre-COVID visit (T1) and a post-COVID visit (T2). During the lockdown, an online compilation of validated psychological tests (SRQ-20, EQ5D, SF-12 and STAI) and a specifically formulated questionnaire for NAFLD was presented to our cohort and completed by 14 consenting patients. Patients who had lost more than 5% of the initial weight at T1 (9 subjects, 21%) maintained the results even at T2, with an overall reduction in BMI and liver stiffness; patients who had not lost the desired weight at T1 (34 subjects, 79%) displayed a further increase in BMI and visceral adiposity at T2. Of interest is that patients in the latter group reported signs of psychological suffering. Our data demonstrated that the setting of good counseling was effective in controlling the metabolic disorder underlying NAFLD in our cohort of outpatients. Given the need for patients to play an active role in the behavioral therapy for NAFLD, we advocate that a multidisciplinary approach be adopted, including a psychological support to obtain the best results over time.
非酒精性脂肪性肝病(NAFLD)是一种潜在进展性疾病,其特征为肝细胞内脂肪含量超过 5%,代表代谢综合征(MetS)的肝脏表现。初始体重至少降低 5-7%可改善 NAFLD 的代谢特征。我们的研究目的是评估 COVID-19 封锁对意大利非进展性 NAFLD 门诊患者队列的影响。我们在我们的中心确定了 43 名患者,他们有 3 次就诊时间点:首次就诊(T0)时提供了控制 MetS 的行为指导,COVID-19 前就诊(T1)和 COVID-19 后就诊(T2)。在封锁期间,向我们的队列呈现了在线编制的经过验证的心理测试(SRQ-20、EQ5D、SF-12 和 STAI)和专门为 NAFLD 制定的问卷,并由 14 名同意的患者完成。在 T1 时体重减轻超过 5%的患者(9 名患者,21%)保持了结果,即使在 T2 时,BMI 和肝硬度也有总体降低;在 T1 时没有减轻所需体重的患者(34 名患者,79%)在 T2 时显示出 BMI 和内脏脂肪增加。有趣的是,后者组的患者报告了心理痛苦的迹象。我们的数据表明,在我们的门诊患者队列中,良好咨询的设定有效地控制了 NAFLD 潜在的代谢紊乱。鉴于患者需要在 NAFLD 的行为治疗中发挥积极作用,我们提倡采用多学科方法,包括心理支持,以随着时间的推移获得最佳结果。